Reece Caldwell

Medical Oncologist

[Reece Caldwell @75d6345cf58e4ce]

@hometelecomcare is your service down around the Battersea area

[udaibanerji @udai_banerji]

CHK1 inhibitor SRA737 with low dose gemcitabine for smarter kinder treatments. Fields of DDRi /cell cycle response have more to give.. https://t.co/cbFdcF31jm. @CCR_AACR Collaborative academic drug discovery @ICR_London @royalmarsdenNHS @ECMC_UK @CRU_UK @cancerBRC @sierraoncology

[Australian Rare Cancer (ARC) Portal @rare_arc]

Updated CheckMate 743 data presented at ESMO shows nearly 1 in 4 patients with pleural malignancy continue to benefit from combination nivolumab plus ipilimumab at 3 years.

Learn more - https://t.co/lzHyvOnZW8

#ESMO21 #immunotherapy #rarecancer # mesothelioma

[Australian Rare Cancer (ARC) Portal @rare_arc]

Meet our newest collaborative partner - @NECancerAus

@NECancerAus is Australia’s only #notforprofit charity focused on neuroendocrine tumours. Unfortunately these tumours are often disguised by common conditions & are difficult to diagnose.

Learn more - https://t.co/BbMt1186vj

[Paolo Tarantino @PTarantinoMD]

Metaplastic BC is a rare, aggressive variant of BC. In this ph2 trial of nivo+ipi for advanced metaplastic BC, 3/17 pts achieved a response

Most importantly, all three responses are ongoing >2 years!

Responders where not identified by PDL1, TMB or TILs

https://t.co/Ej5FeGj4SX

[Australian Rare Cancer (ARC) Portal @rare_arc]

@rare_arc has been invited to present at the upcoming @COSAoncology Annual Scientific Meeting (NOV 16-18)

👨‍⚕️ Professor Clare Scott
📆 17/11
⏰ 3:30pm

👨‍⚕️ Dr Reece Caldwell
📆 18/11
⏰ 11 am

Learn more about COSA 2021 and our presenters here - https://t.co/IGEO73MkVl

#COSA21

[Australian Rare Cancer (ARC) Portal @rare_arc]

News in the world of Rare Cancers

A recent presentation of data from the #CheckMate743 study at #ESMO2021 conference has highlighted the importance of immunotherapy as first-line treatment for patients with malignant pleural mesothelioma.

Learn more - https://t.co/eZT6rMdJ9v

[Australian Rare Cancer (ARC) Portal @rare_arc]

The AGITG’s NABNEC study aims to recruit 58 patients by the end of December 2021. We encourage you to refer any eligible patients to one of the 18 recruiting sites around the country.

More information - https://t.co/xhYhtQp83K

#cancer #precisionmedicine #curecancer

[Australian Rare Cancer (ARC) Portal @rare_arc]

More than 1/2 of gynaecological cancers are rare cancers.

WomenCan brings together Australian artists to raise funds for @anzgog’s pioneering research. Their #HonourHer2021 campaign for #GynaecologicalCancerAwarenessMonth honours women affected by gynaecological cancer.

[ANZGOG @anzgog]

Survivors Teaching Students (STS) is ANZGOG’s education program where gynaecological cancer survivors & caregivers share their experiences with the diseases with health professional students to help improve earlier future diagnosis👩‍🏫

#GynaecologicalCancerAwarenessMonth

[Australian Rare Cancer (ARC) Portal @rare_arc]

This month's Rare Cancer Spotlight - Mesothelioma (1)

AUS has one of the highest incidence rates of mesothelioma -aprox 3 in 100k people. This rare and aggressive cancer has no cure. Average time between diagnosis & death is around 11 months

Learn more - https://t.co/e4cDmTNWo6

[Australian Rare Cancer (ARC) Portal @rare_arc]

We're back with our latest Rare Cancer Spotlight: Low Grade Serous Ovarian Cancer

Low Grade Serous Ovarian Cancer is a rare tumour that affects many young, Australian Women.

Learn more here - https://t.co/BbgIGTOpYS

#PrecisionMedicine #Cancer

[Australian Rare Cancer (ARC) Portal @rare_arc]

Rare Cancer Spotlight: Low Grade Serous Ovarian Cancer (2)

ARC Portal, in collaboration with WEHI-Stafford Fox Rare Cancer Program, the MoST Program and @OmicoAustralia is helping Australian Oncologists & their patients access molecular testing.

More - https://t.co/BbgIGTOpYS

[Australian Rare Cancer (ARC) Portal @rare_arc]

The AGITG’s NABNEC study in its final stages of recruitment!

The trial studies two different chemotherapy treatments for patients with grade 3 advanced gastrointestinal Neuroendocrine Carcinomas (NECs).

More information - https://t.co/xhYhtQp83K

#PrecisionMedicine #Cancer

[Australian Rare Cancer (ARC) Portal @rare_arc]

Do you have a question about the ARC Portal?

@DrChloeG will be presenting an update on the Australian Rare Cancer Portal tomorrow at the @MOGA_ORG Annual Scientific Meeting.

Submit your questions for Chloe here - https://t.co/y5xRB8LSB8

#MOGAASM21 #Cancer #RareCancer

[Australian Rare Cancer (ARC) Portal @rare_arc]

Over one-in-five cancer patients in Western Australia are diagnosed with a rare cancer. The Western Australian Cancer Registry have published the first epidemiological study on rare cancers in WA.

Learn more here - https://t.co/jhfcZoE2fg

#PrecisionMedicine #Cancer #RareCancer

[Australian Rare Cancer (ARC) Portal @rare_arc]

While rare cancers are individually scarce, over one in five cancer patients in WA are diagnosed with a rare cancer. These patients experience significantly worse prognoses vs patients with common cancers

Learn more here - https://t.co/jhfcZoE2fg

#PrecisionMedicine #Cancer

[Chloe @DrChloeG]

Honoured to work with Clare at the Australian Rare Cancer Portal @rare_arc @sashalouise2

[Australian Rare Cancer (ARC) Portal @rare_arc]

We love hearing from our amazing community! If you want to get in touch you can reach us through one of our many social media accounts or via email.

Contact - https://t.co/D2hkZfMhGt
Linkedin - https://t.co/35Ic53bued
FB - https://t.co/27PTbx1H79

#PrecisionMedicine #Cancer

[Australian Rare Cancer (ARC) Portal @rare_arc]

NEWS IN THE WORLD OF RARE CANCER

The TOPOGRAPH database has recently been released by Australian researchers to aid oncologist’s treatment decisions.

Learn more - https://t.co/BKYoPzqOPv

#Cancer #PrecisionMedicine